Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer

Molecular Therapy — Nucleic Acids 2026 Open access

Read full text
Authors: Erick Intriago, Amartya Pal, Anushka Ojha, Mingrui Cui, Ilan Y. Pesselev, Nicolas Coant, Isabel Guo, John Haley, Jingfang Ju
DOI: 10.1016/j.omtn.2026.102997
Cited by: 1
References: 27

Abstract

in the low nanomolar range in NSCLC cell lines. Gem-miR-129 retains same nanomolar activity in both erlotinib- and osimertinib-resistant NSCLC cell lines. This potency is achieved through the dual mechanisms of the multi-targeted tumor suppressor miR-129, which suppresses HMGB1, YAP1, and PBX3, in conjunction with the expected therapeutic contribution of Gem following degradation of Gem-miR-129. A unique feature of Gem-miR-129 is its vehicle-free uptake in cultured NSCLC cells. Gem-miR-129 effectively inhibits NSCLC growth in a mouse model and significantly prolongs survival without overt toxicity under the tested conditions. Overall, Gem-miR-129 provides proof-of-concept for a novel tumor-suppressor miRNA-based therapeutic strategy for NSCLC and for overcoming TKI resistance.

Fields of Study & Subjects

MicroRNA in disease regulation Lung Cancer Treatments and Mutations Biological Research and Disease Studies

Publication details

Journal / source
Molecular Therapy — Nucleic Acids
Publisher
Elsevier BV
Volume
37
Issue
3
Pages
102997–102997
Publication date
1 July 2026
Language
EN